| Assessment Status | Rapid Review Complete |
| HTA ID | 24026 |
| Drug | Pemigatinib |
| Brand | Pemazyre® |
| Indication | Pemigatinib (Pemazyre®) is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 05/07/2024 |
| Rapid review completed | 16/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pemigatinib compared with the current standard-of-care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations. August 2025